Atea Pharmaceuticals News

Hold Rating on Atea Pharmaceuticals: Analysis of Clinical Programs, Financial Health and Future Prospects

TipRanksNov 10, 2023 06:32 ET

Atea Pharmaceuticals Analyst Ratings

BenzingaAug 10, 2023 05:28 ET

Atea Pharmaceuticals (AVIR) Gets a Hold From SVB Securities

TipRanksMay 23, 2023 11:45 ET

Atea Pharmaceuticals (AVIR) Gets a Hold From SVB Securities

TipRanksMay 11, 2023 12:47 ET

Atea Pharmaceuticals (AVIR) Gets a Hold From J.P. Morgan

TipRanksMar 16, 2023 12:31 ET

JPMorgan Adjusts Atea Pharmaceuticals Price Target to $8 From $12, Maintains Neutral Rating

MT NewswiresMar 16, 2023 09:29 ET

JP Morgan Maintains Neutral on Atea Pharmaceuticals, Lowers Price Target to $8

BenzingaMar 16, 2023 08:51 ET

SVB Securities Reaffirms Their Hold Rating on Atea Pharmaceuticals (AVIR)

TipRanksMar 3, 2023 01:21 ET

SVB Securities Adjusts Atea Pharmaceuticals' Price Target to $6 From $8, Keeps Market Perform Rating

MT NewswiresJan 27, 2023 10:47 ET

Atea Pharmaceuticals (AVIR) Receives a Hold From SVB Securities

TipRanksJan 27, 2023 07:27 ET

Atea Pharmaceuticals Analyst Ratings

Benzinga Analyst RatingsJan 27, 2023 06:48 ET

SVB Leerink Maintains Market Perform on Atea Pharmaceuticals, Lowers Price Target to $6

Benzinga Real-time NewsJan 27, 2023 06:48 ET

Morgan Stanley Sticks to Its Sell Rating for Atea Pharmaceuticals (AVIR)

TipRanksJan 24, 2023 11:30 ET

Morgan Stanley Adjusts Price Target on Atea Pharmaceuticals to $4 From $7, Maintains Underweight Rating

MT NewswiresJan 24, 2023 09:50 ET

Atea Pharmaceuticals Analyst Ratings

Benzinga Analyst RatingsJan 24, 2023 08:17 ET

Morgan Stanley Maintains Underweight on Atea Pharmaceuticals, Lowers Price Target to $4

Benzinga Real-time NewsJan 24, 2023 08:17 ET

Atea Pharmaceuticals (AVIR) Gets a Hold From SVB Securities

TipRanksNov 9, 2022 23:40 ET

SVB Securities Keeps Their Hold Rating on Atea Pharmaceuticals (AVIR)

TipRanksOct 17, 2022 00:50 ET

Morgan Stanley Sticks to Its Sell Rating for Atea Pharmaceuticals (AVIR)

TipRanksAug 15, 2022 08:45 ET

Atea Pharmaceuticals Price Target Raised to $7.00/Share From $6.00 by Morgan Stanley

Dow JonesAug 15, 2022 08:18 ET